Novartis AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NVSEF | AMGN | AZN | BIIB | MRK | SNY | |
|---|---|---|---|---|---|---|
| Market cap | 273.51B | 233.82B | 256.54B | 34.37B | 360.08B | 97.31B |
| P/E (TTM) | 21.7 | 26.9 | 23.8 | 41.3 | 115.8 | 21.4 |
| Forward P/E | — | 17.7 | 14.6 | 14.1 | 15.7 | 7.7 |
| Price/book | 6.6 | 20.0 | 5.1 | 1.8 | 8.6 | 1.3 |
| Dividend yield | 3.29% | 2.33% | 1.94% | — | 2.33% | 5.96% |
| 1-year change | +9.97% | +42.58% | −1.39% | +58.66% | +69.08% | −18.34% |
| Today | −0.29% | −0.35% | −0.76% | −1.15% | +0.52% | +0.79% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All NVSEF news ›Novartis halts mid-stage trial for kidney drug, Fabhalta, in lupus nephritis
Novartis (NVS) ends a mid-stage trial for kidney drug Fabhalta (iptacopan) in lupus nephritis because of strategic considerations. Read more here. TBE/iStock Editorial via Getty Images Novartis (NVS) has terminated a mid-stage trial for…
Novartis in Society Integrated Report
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
The Novartis US Foundation
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
Novartis commitment to patients and caregivers
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
Reimagining Healthcare in Challenging Times: Novartis in Society US Report for 2020
Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
Vanda Pharmaceuticals is suspending the development of a social anxiety drug licensed from Novartis after the drug showed no significant benefit in a late-stage study. The investigational drug, called VQW-765, failed to significantly ease…
$237.7M Loan Secured for Novartis-Anchored Pathway Triangle Biomanufacturing Campus in Morrisville
BioBuzz $237.7M Loan Secured for Novartis-Anchored Pathway Triangle Biomanufacturing Campus in Morrisville JLL Capital Markets announced on October 12, 2026 that it has arranged $237.7 million in financing for Phase I of Pathway Triangle,…
Novartis Egypt underscores importance of early detection, treatment adherence in breast cancer care
Breast cancer is the most common cancer among women in Egypt, accounting for 37.3% of all cancer diagnoses among women. According to estimates from the International Agency for Research on Cancer, Egypt recorded 26,052 new cases and 9,717…
CAS and Novartis collaborate to advance access to reaction data and AI research
Federation: Log in through a federation service that connects your organization to multiple systems. Use this option if your organization instructs you to use federated sign-in. CAS and Novartis collaborate to advance access to reaction…
Royalty Pharma Announces Update on Novartis Phase 3 Topline Results for Pelacarsen
Royalty Pharma plc had announced an update on Novartis? Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic... Royalty Pharma plc had announced an update on…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com26
-
tradingview.com5
-
medicaldialogues.in4
-
biospace.com3
-
news.bloomberglaw.com3
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 118 articles, not a forecast.